EOMES overexpression leads to loss of CD226 in CD8+ tumor-infiltrating lymphocytes (TILs), suppression of the function of CD8+ T cells, and decrease in the efficacy of cancer immunotherapy [156]. Here, CD8A is linked to cancer.